Study Evaluating the Safety and Efficacy of AR-15512 (COMET-3)
Status:
Not yet recruiting
Trial end date:
2023-05-01
Target enrollment:
Participant gender:
Summary
This will be a Phase 3, multicenter, vehicle-controlled, double-masked, randomized study
conducted at approximately 20 sites in the United States. All subjects enrolled will have dry
eye disease (DED). The study will consist of Screening (Day -14) and Baseline (Day 1) visits
as well as visits at Day 7, Day 14, Day 28, and Day 90 (Study Exit).